PercepTx takes a high-throughput approach to novel antibody-drug conjugates (ADCs), creating more effective cancer treatments. We have built a nimble drug discovery and development operation that combines proprietary computational and modeling platforms with decades of preclinical expertise. Our platforms allow us to find and develop assets with a large therapeutic window, eliminating mediocre targets early and accelerating the best to the finish. We plan to identify and develop a pipeline of 10 ADCs to IND over the next 4-5 years.